Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Amanda McClure

Nurse Practitioner, Adult Health Fayetteville, AR Nurse Practitioner

NPI 1922566785 CMS profile 10700698

3344 N Futrall Dr, Fayetteville, AR 72703

Open in the dashboard

General payments

$8,741

347 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amanda McClure of Fayetteville, AR is reported in the CMS Open Payments database as having received $8,741 across 347 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,325 77
2024 General $1,185 29
2023 General $2,096 94
2022 General $1,730 77
2021 General $1,404 70

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amanda McClure
  • Nurse Practitioner, Adult Health median
  • Middle half of Nurse Practitioner, Adult Health
  • National median

In program year 2025, general payments to Amanda McClure were reported at $2,325. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.

Show as a table
Year Amanda McClure Nurse Practitioner, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,404 $138 $43–$438 $132
2022 $1,730 $165 $54–$494 $149
2023 $2,096 $178 $61–$549 $160
2024 $1,185 $186 $62–$575 $164
2025 $2,325 $184 $59–$580 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $1,772 29 payments
  2. Amgen Inc. $1,396 55 payments
  3. Sanofi-Aventis U.S. LLC $593 23 payments
  4. Novo Nordisk Inc $583 27 payments
  5. Lilly USA, LLC $518 23 payments
  6. Dexcom, Inc. $508 18 payments
  7. Insulet Corporation $448 20 payments
  8. Xeris Pharmaceuticals, Inc. $441 19 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $366 23 payments
  10. Abbott Laboratories $310 23 payments
  11. Other $1,805 87 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,741 347 payments
Products named General payments · program years 2021–2025
  1. MINIMED 780G $1,538 21 payments
  2. EVENITY $845 33 payments
  3. Prolia $448 25 payments
  4. Omnipod $448 20 payments
  5. RYBELSUS $327 19 payments
  6. TZIELD $321 12 payments
  7. Ozempic $315 18 payments
  8. Repatha $312 13 payments
  9. JARDIANCE $288 18 payments
  10. FreeStyle Libre $272 21 payments
  11. Other $4,941 208 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 44 drugs

Part D claims

1,912

Median for Nurse Practitioner: 389

Drug cost

$1,123,365

Median for Nurse Practitioner: $21,885

Branded share of claims

74.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 223 $253,492
Mounjaro Tirzepatide Brand 197 $246,554
Trulicity Dulaglutide Brand 101 $135,005
Jardiance Empagliflozin Brand 61 $60,144
Fiasp Flextouch Insulin Aspart (Niacinamide) Brand 62 $58,745
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 42 $42,912
Humulin R U-500 Kwikpen Insulin Regular, Human Brand 37 $42,303
Tresiba Flextouch U-100 Insulin Degludec Brand 42 $29,117
Tresiba Flextouch U-200 Insulin Degludec Brand 30 $27,937
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 25 $25,966

The 10 drugs with the highest cost, of 44 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$22,285

Medicare's payments for the services billed

Medicare patients

1,545

Average age 73

Services billed

1,693

1,403 women, 142 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Osteoporosis 51%
Arthritis 50%
Diabetes 29%
Chronic kidney disease 29%
Depression 29%
Ischemic heart disease 23%
Cancer 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $31
  • Lilly USA, LLC $16
$48 61 —
EVENITY
  • Amgen Inc. $45
$45 — —
Prolia
  • Amgen Inc. $45
$45 — —
TZIELD
  • SANOFI-AVENTIS U.S. LLC $36
$36 — —
SYNTHROID
  • AbbVie, Inc. $25
$25 62 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

347 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Adult Health in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record